Nivolumab + Ipilimumab
Treatment for Kidney Cancer
Typical Dosage: Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses, then Nivolumab 240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Effectiveness
85%
Safety Score
35%
Clinical Trials
96
Participants
550
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
35
DangerousModerateSafe
Treatment Details
Dosage Range
Nivolumab 3 mg/kg IV + Ipilimumab 1 mg/kg IV every 3 weeks for 4 doses, then Nivolumab 240 mg IV every 2 weeks or 480 mg IV every 4 weeks
Time to Effect
2-3 months
Treatment Duration
Fixed Ipilimumab for 4 doses, then Nivolumab until progression or unacceptable toxicity
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$200,000
Monitoring:$20,000
Side Effect Mgmt:$15,000
Total Annual:$235,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$287,000/QALY
QALYs Gained
1.4
Outcome-Based Costs
Cost per Responder
$470,000
Cost per Remission
$1,678,571
Comparison vs Sunitinib
Cost Difference
+$115,000/year
More expensive
QALY Difference
+1.40 QALYs
Better outcomes
Dominance
No dominance
Nivolumab + Ipilimumab Outcomes
for Kidney Cancer
Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+50%
Remission Rate
+14%
Common Side Effects
Fatigue
+52%
Diarrhea
+49%
Rash
+31%
Pruritus
+26%
Nausea
+25%
Colitis
+10%
Active Clinical Trials
7 active trials recruiting for Nivolumab + Ipilimumab in Kidney Cancer
CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy
NCT05215470ACTIVE NOT RECRUITINGPHASE2
100 participants
INTERVENTIONAL
Ribeirão Preto, Brazil
Started: Jan 18, 2022
Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)
NCT03203473ACTIVE NOT RECRUITINGPHASE2
85 participants
INTERVENTIONAL
La Jolla, United States +7 more
Started: Oct 26, 2017
SBRT With Combination Ipilimumab/Nivolumab for Metastatic Kidney Cancer
NCT04090710ACTIVE NOT RECRUITINGPHASE2
66 participants
INTERVENTIONAL
Melbourne, Australia +6 more
Started: Jan 29, 2020
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer
NCT03873402ACTIVE NOT RECRUITINGPHASE3
437 participants
INTERVENTIONAL
Washington D.C., United States +77 more
Started: Jun 21, 2019
Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.
NCT05501054ACTIVE NOT RECRUITINGPHASE1, PHASE2
50 participants
INTERVENTIONAL
Durham, United States +2 more
Started: Feb 9, 2023
A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)
NCT07188896NOT YET RECRUITINGPHASE2
120 participants
INTERVENTIONAL
Started: Feb 1, 2026
Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NCT04413123ACTIVE NOT RECRUITINGPHASE2
60 participants
INTERVENTIONAL
Boston, United States +3 more
Started: Nov 5, 2020
Completed Clinical Trials
7 completed trials for Nivolumab + Ipilimumab in Kidney Cancer
A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
NCT04513522COMPLETEDPHASE4
101 participants
INTERVENTIONAL
Ahmedabad, India +10 more
Started: Dec 17, 2020
An Investigational Immuno-Therapy Safety and Efficacy Study of Multiple Administration Regimens for Nivolumab Plus Ipilimumab in Subjects With Renal Cell Carcinoma
NCT03029780COMPLETEDPHASE2
104 participants
INTERVENTIONAL
Jacksonville, United States +10 more
Started: Feb 16, 2017
A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney
NCT03138512COMPLETEDPHASE3
1.64K participants
INTERVENTIONAL
Birmingham, United States +199 more
Started: Jul 7, 2017
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma
NCT03297593COMPLETEDPHASE2
74 participants
INTERVENTIONAL
Aarau, Switzerland +13 more
Started: Dec 13, 2017
Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab
NCT03126331COMPLETEDPHASE2
26 participants
INTERVENTIONAL
Cleveland, United States
Started: Aug 3, 2017
Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Renal Cell Carcinoma
NCT02917772COMPLETEDPHASE2
200 participants
INTERVENTIONAL
Linz, Austria +34 more
Started: Oct 1, 2016
A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer
NCT02982954COMPLETEDPHASE4
211 participants
INTERVENTIONAL
Muscle Shoals, United States +60 more
Started: Jan 16, 2017
Showing 20 of 98 total trials